{
    "clinical_study": {
        "@rank": "124556", 
        "arm_group": [
            {
                "arm_group_label": "VS101 Insert Dose A", 
                "arm_group_type": "Experimental", 
                "description": "VS101 Insert Dose A placed under the conjunctiva"
            }, 
            {
                "arm_group_label": "VS101 Insert Dose B", 
                "arm_group_type": "Experimental", 
                "description": "VS101 Insert Dose B placed under the conjunctiva"
            }, 
            {
                "arm_group_label": "VS101 Insert Dose C", 
                "arm_group_type": "Experimental", 
                "description": "VS101 Insert Dose C placed under the conjunctiva"
            }, 
            {
                "arm_group_label": "Latanoprost 0.005% eye drops", 
                "arm_group_type": "Active Comparator", 
                "description": "Latanoprost 0.005% eye drops administered once daily on the eye"
            }
        ], 
        "brief_summary": {
            "textblock": "Slow release formulation of latanoprost is compared for safety and pressure-lowering\n      efficacy with topically administration of commercially available latanoprost in patient with\n      glaucoma and ocular hypertension"
        }, 
        "brief_title": "A Phase 1/2 Multicenter, Randomized, Study to Evaluate the Safety and Efficacy of VS101 Subconjunctival Latanoprost Insert in Subjects With Open-Angle Glaucoma or Ocular Hypertension", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Open Angle Glaucoma", 
            "Ocular Hypertension"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Glaucoma", 
                "Glaucoma, Open-Angle", 
                "Hypertension", 
                "Ocular Hypertension"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age > 18\n\n          -  Open angle glaucoma or Ocular Hypertension\n\n        Exclusion Criteria:\n\n          -  uncontrolled medical conditions\n\n          -  wearing of contact lenses"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 30, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02129673", 
            "org_study_id": "VS101-CS201"
        }, 
        "intervention": [
            {
                "arm_group_label": "VS101 Insert Dose A", 
                "description": "Sustained release of latanoprost into the eye", 
                "intervention_name": "VS101 Insert Dose A", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "VS101 Insert Dose B", 
                "description": "Sustained release of latanoprost into the eye", 
                "intervention_name": "VS101 Insert Dose B", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "VS101 Insert Dose C", 
                "description": "Sustained release of latanoprost into the eye", 
                "intervention_name": "VS101 Insert Dose C", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Latanoprost 0.005% eye drops", 
                "description": "Latanoprost 0.005% eye drops administered once daily on the eye", 
                "intervention_name": "Latanoprost 0.005% eye drops", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Tetrahydrozoline", 
                "Latanoprost"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Glaucoma", 
            "Intra-ocular pressure", 
            "Slow Release", 
            "Controlled release"
        ], 
        "lastchanged_date": "May 1, 2014", 
        "number_of_arms": "4", 
        "official_title": "A Phase 1/2 Multicenter, Randomized, Controlled Dose-Finding Study to Evaluate the Safety and Ocular Hypotensive Efficacy of 3 Dose Levels of the VS101 Subconjunctival Latanoprost Insert for 3 Months in Subjects With Open-Angle Glaucoma or Ocular Hypertension", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Intra-ocular pressure", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02129673"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Intra-ocular pressure", 
                "safety_issue": "No", 
                "time_frame": "Week 8"
            }, 
            {
                "measure": "Intra-ocular pressure", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }
        ], 
        "source": "ViSci Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "ViSci Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}